FDA grants Roche's Avastin Priority Review for recurrent platinum-resistant ovarian cancer

Roche today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Avastin (bevacizumab) plus chemotherapy for the treatment of women with recurrent platinum-resistant ovarian cancer.
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news